KR900017592A - Tnf의 부작용을 감소시키기 위한 용도 및 약제 - Google Patents
Tnf의 부작용을 감소시키기 위한 용도 및 약제 Download PDFInfo
- Publication number
- KR900017592A KR900017592A KR1019890005809A KR890005809A KR900017592A KR 900017592 A KR900017592 A KR 900017592A KR 1019890005809 A KR1019890005809 A KR 1019890005809A KR 890005809 A KR890005809 A KR 890005809A KR 900017592 A KR900017592 A KR 900017592A
- Authority
- KR
- South Korea
- Prior art keywords
- tnf
- side effects
- paf
- antagonist
- web2347
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (6)
- 종양 괴사 인자(TNF-α 및 TNF-β)를 치료용으로 사용하는 데 있어서의 바람직하지 못한 부작용을 감소시키기 위한, PAF-길항성 화합물을 함유함을 특징으로 하는 약제.
- TNF및 PAF-길항성 화합물을 함유함을 특징으로 하는 주사용 액제.
- TNF를 치료용으로 사용하는 데 있어서의 바람직하지 못한 부작용을 감소시키기 위한 PAF-길항 물질의 용도.
- 제1항에 있어서, PAF-길항 물질이 임의로는산부가염의 형태인 WEB2086, Web2170 또는 Web2347임을 특징으로 하는 약제.
- 제2항에 있어서, PAF-길항 물질이 임의로는산부가염의 형태인 WEB2086, Web2170 또는 Web2347임을 특징으로 하는 약제.
- TNF를 치료용으로 사용하는 데 있어서의 바람직하지 못한 부작용을 감소시키기 위한, 임의로는 산 부가염의 형태인, WEB2086, Web2170 또는 Web2347의 용도.※ 참고사항 : 최초출원내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEP3816169.9 | 1988-05-11 | ||
DE3816169A DE3816169A1 (de) | 1988-05-11 | 1988-05-11 | Verwendung und mittel zur verminderung der nebenwirkungen von tnf |
Publications (1)
Publication Number | Publication Date |
---|---|
KR900017592A true KR900017592A (ko) | 1990-12-19 |
Family
ID=6354207
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019890005809A KR900017592A (ko) | 1988-05-11 | 1989-05-01 | Tnf의 부작용을 감소시키기 위한 용도 및 약제 |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP0341558B1 (ko) |
JP (1) | JP2709139B2 (ko) |
KR (1) | KR900017592A (ko) |
AT (1) | ATE78695T1 (ko) |
AU (1) | AU614607B2 (ko) |
CA (1) | CA1336825C (ko) |
DE (2) | DE3816169A1 (ko) |
DK (1) | DK220789A (ko) |
ES (1) | ES2042864T3 (ko) |
GR (1) | GR3005387T3 (ko) |
HU (1) | HUT52381A (ko) |
IL (1) | IL90206A0 (ko) |
ZA (1) | ZA893259B (ko) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3735525C2 (de) * | 1987-10-20 | 1997-02-20 | Korth Ruth Maria | Verfahren zur Bestimmung der Wirksamkeit von paf-Acether-Rezeptor-Antagonisten |
GB8926611D0 (en) * | 1989-11-24 | 1990-01-17 | Xenova Ltd | Compound and its use |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988002632A1 (en) * | 1986-10-16 | 1988-04-21 | President And Fellows Of Harvard College | Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseases |
-
1988
- 1988-05-11 DE DE3816169A patent/DE3816169A1/de not_active Withdrawn
-
1989
- 1989-05-01 KR KR1019890005809A patent/KR900017592A/ko not_active Application Discontinuation
- 1989-05-03 EP EP89107969A patent/EP0341558B1/de not_active Expired - Lifetime
- 1989-05-03 ES ES89107969T patent/ES2042864T3/es not_active Expired - Lifetime
- 1989-05-03 DE DE8989107969T patent/DE58901920D1/de not_active Expired - Lifetime
- 1989-05-03 AT AT89107969T patent/ATE78695T1/de not_active IP Right Cessation
- 1989-05-03 ZA ZA893259A patent/ZA893259B/xx unknown
- 1989-05-04 CA CA000598696A patent/CA1336825C/en not_active Expired - Fee Related
- 1989-05-05 DK DK220789A patent/DK220789A/da not_active Application Discontinuation
- 1989-05-05 AU AU34064/89A patent/AU614607B2/en not_active Ceased
- 1989-05-05 IL IL90206A patent/IL90206A0/xx unknown
- 1989-05-05 HU HU892180A patent/HUT52381A/hu unknown
- 1989-05-06 JP JP1113985A patent/JP2709139B2/ja not_active Expired - Lifetime
-
1992
- 1992-08-06 GR GR920401724T patent/GR3005387T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
GR3005387T3 (ko) | 1993-05-24 |
DK220789A (da) | 1989-11-12 |
DK220789D0 (da) | 1989-05-05 |
AU614607B2 (en) | 1991-09-05 |
JPH0276825A (ja) | 1990-03-16 |
IL90206A0 (en) | 1989-12-15 |
HUT52381A (en) | 1990-07-28 |
EP0341558A3 (en) | 1990-05-09 |
AU3406489A (en) | 1989-11-16 |
EP0341558B1 (de) | 1992-07-29 |
DE3816169A1 (de) | 1989-11-23 |
CA1336825C (en) | 1995-08-29 |
DE58901920D1 (de) | 1992-09-03 |
JP2709139B2 (ja) | 1998-02-04 |
ATE78695T1 (de) | 1992-08-15 |
EP0341558A2 (de) | 1989-11-15 |
ZA893259B (en) | 1991-01-30 |
ES2042864T3 (es) | 1993-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR920002144A (ko) | 아연 l-카르노신 염 또는 이의 착화합물을 유효성분으로 함유하는 염증성 장질환 예방 및 치료제 | |
FI875533A0 (fi) | Insulinpreparat foer non-parenteral dosering. | |
KR880012217A (ko) | 캘콘 유도체를 사용한 종량 조직의 증식 억제방법 | |
KR920702216A (ko) | 아세틸 d-카르니틴의 녹내장 치료에의 용도 | |
DK0724885T3 (da) | Pernasal sammensætning og pernasalt præparat indeholdende dette | |
DK581685D0 (da) | Transderimalt system for timolol-indgift | |
ATE495793T1 (de) | Antitumorzusammensetzungen welche ecteinascidin 743 enthalten | |
DE68909409T2 (de) | Heilmitteldosierung zur verabreichung an fische. | |
KR950007848A (ko) | (S)-(-)-α-에틸-2-옥소-1-피롤리딘아세트아미드를 사용한 불안치료방법 | |
ATE46444T1 (de) | Rektale verabreichung von arzneimitteln mit hilfsmitteln. | |
KR890700026A (ko) | 건선 치료에 있어서 주석 프로토포르피린 및 주석 메조포르피린의 용도 | |
ATE97001T1 (de) | Topisch anzuwendende defibrotid enthaltende arzneizubereitungen. | |
KR900017592A (ko) | Tnf의 부작용을 감소시키기 위한 용도 및 약제 | |
KR910009267A (ko) | 우울증의 치료방법 | |
KR940008678A (ko) | 주사용 메스나 액제 | |
KR920021144A (ko) | 역류성 식도염을 치료하기위한 니자티딘의 용도 | |
KR890701526A (ko) | 각화증 치료제 | |
KR920017668A (ko) | 암 전이 억제 또는 예방 방법 및 이를 위한 제제 | |
KR870010871A (ko) | 재조합 인체 알파 인터페론에 의한 기저세포 암종의 병소내적 치료방법 | |
KR910021244A (ko) | 당뇨병성 괴저 치료제 | |
KR920019349A (ko) | 불안을 치료하기 위한 r(+)-3-아미노-1-하이드록시-피롤리딘-2-온의 용도 | |
KR880009656A (ko) | 국소 치근막 질환의 치료 또는 예방법 | |
KR900017599A (ko) | 종양 치료용 약학 조성물 | |
KR900701311A (ko) | 재조합 사람 α-인터페론을 병소내로 투여하여 편평세포 암을 치료하는 방법 | |
KR930702016A (ko) | 골다공증 치료제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |